269 related articles for article (PubMed ID: 16928220)
1. Tolerance to H2 receptor antagonist correlates well with the decline in efficacy against gastroesophageal reflux in patients with gastroesophageal reflux disease.
Furuta K; Adachi K; Komazawa Y; Mihara T; Miki M; Azumi T; Fujisawa T; Katsube T; Kinoshita Y
J Gastroenterol Hepatol; 2006 Oct; 21(10):1581-5. PubMed ID: 16928220
[TBL] [Abstract][Full Text] [Related]
2. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
Adachi K; Hashimoto T; Komazawa Y; Mihara T; Furuta K; Fujishiro H; Ishihara S; Amano Y; Hattori S; Kinoshita Y
Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
[TBL] [Abstract][Full Text] [Related]
3. Helicobacter pylori infection prevents the occurrence of the tolerance phenomenon of histamine H2 receptor antagonists.
Fujisawa T; Adachi K; Komazawa Y; Mihara T; Azumi T; Katsube T; Furuta K; Kazumori H; Kinoshita Y
Aliment Pharmacol Ther; 2004 Sep; 20(5):559-65. PubMed ID: 15339327
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of the speed of acid-suppressing effects of oral administration of cimetidine and famotidine.
Adachi K; Komazawa Y; Mihara T; Azumi T; Fujisawa T; Katsube T; Furuta K; Kinoshita Y
J Gastroenterol Hepatol; 2005 Jul; 20(7):1012-5. PubMed ID: 15955208
[TBL] [Abstract][Full Text] [Related]
5. Effect of Helicobacter pylori status on intragastric pH during administration of lafutidine or famotidine.
Koike T; Ohara S; Sehine H; Kawamura M; Abe Y; Inomata Y; Iijima K; Imatani A; Shimosegawa T
Hepatogastroenterology; 2007 Jun; 54(76):1280-4. PubMed ID: 17629089
[TBL] [Abstract][Full Text] [Related]
6. [Gastroesophageal reflux disease in preschool children with asthma].
Yoshida Y; Kameda M; Nishikido T; Takamatu I; Doi S
Arerugi; 2008 May; 57(5):529-35. PubMed ID: 18520174
[TBL] [Abstract][Full Text] [Related]
7. Addition of a H2 receptor antagonist to PPI improves acid control and decreases nocturnal acid breakthrough.
Mainie I; Tutuian R; Castell DO
J Clin Gastroenterol; 2008 Jul; 42(6):676-9. PubMed ID: 18496394
[TBL] [Abstract][Full Text] [Related]
8. Comparison of gastric pH with omeprazole magnesium 20.6 mg (Prilosec OTC) o.m. famotidine 10 mg (Pepcid AC) b.d. and famotidine 20 mg b.d. over 14 days of treatment.
Miner PB; Allgood LD; Grender JM
Aliment Pharmacol Ther; 2007 Jan; 25(1):103-9. PubMed ID: 17229225
[TBL] [Abstract][Full Text] [Related]
9. [Effect of H2-blockers and proton pump inhibitors on intragastric acidity and intraesophageal pH in patients with gastroesophageal reflux disease].
Ivanov AN; Iakovenko EP; Iakovenko AV
Eksp Klin Gastroenterol; 2004; (4):16-20, 107. PubMed ID: 15568661
[TBL] [Abstract][Full Text] [Related]
10. Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease.
Fujiwara Y; Higuchi K; Nebiki H; Chono S; Uno H; Kitada K; Satoh H; Nakagawa K; Kobayashi K; Tominaga K; Watanabe T; Oshitani N; Arakawa T
Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():10-8. PubMed ID: 15943841
[TBL] [Abstract][Full Text] [Related]
11. Reversal of the tolerance phenomenon by the intermittent administration of a histamine H2-receptor antagonist.
Takahashi M; Katayama Y
J Gastroenterol Hepatol; 2010 Sep; 25(9):1493-7. PubMed ID: 20796145
[TBL] [Abstract][Full Text] [Related]
12. Long-term gastroesophageal reflux disease therapy improves reflux symptoms in elderly patients: five-year prospective study in community medicine.
Miyamoto M; Haruma K; Kuwabara M; Nagano M; Okamoto T; Tanaka M
J Gastroenterol Hepatol; 2007 May; 22(5):639-44. PubMed ID: 17444849
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of gastrosidine (famotidine) in the treatment of gastroesophageal reflux at the reflux esophagitis stage].
Vasil'ev IuV; Li IA
Eksp Klin Gastroenterol; 2002; (4):30-3, 131. PubMed ID: 12503271
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the acidity index and integrated intragastric acidity in 645 patients presenting with gastroesophageal reflux disease symptoms.
Blonski WC; Shih GL; Brensinger CM; Katzka DA; Metz DC
Scand J Gastroenterol; 2006 Apr; 41(4):382-9. PubMed ID: 16635904
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic approaches to reflux disease, focusing on acid secretion.
Kinoshita Y; Adachi K; Fujishiro H
J Gastroenterol; 2003 Mar; 38 Suppl 15():13-9. PubMed ID: 12698865
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of hydrotalcite compared with OTC famotidine in the on-demand treatment of gastroesophageal reflux disease: a non-inferiority trial.
Konturek JW; Beneke M; Koppermann R; Petersen-Braun M; Weingärtner U
Med Sci Monit; 2007 Jan; 13(1):CR44-9. PubMed ID: 17179910
[TBL] [Abstract][Full Text] [Related]
17. Famotidine in gastroesophageal reflux disease (GERD).
Wesdorp IC
Hepatogastroenterology; 1992 Feb; 39 Suppl 1():24-6. PubMed ID: 1577391
[TBL] [Abstract][Full Text] [Related]
18. Medical therapy for gastroesophageal reflux disease in 2007.
Katz PO
Rev Gastroenterol Disord; 2007; 7(4):193-203. PubMed ID: 18192955
[TBL] [Abstract][Full Text] [Related]
19. Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration.
Lachman L; Howden CW
Am J Gastroenterol; 2000 Jan; 95(1):57-61. PubMed ID: 10638559
[TBL] [Abstract][Full Text] [Related]
20. Tolerance to famotidine and ranitidine treatment after 14 days of administration in healthy subjects without Helicobacter pylori infection.
Komazawa Y; Adachi K; Mihara T; Ono M; Kawamura A; Fujishiro H; Kinoshita Y
J Gastroenterol Hepatol; 2003 Jun; 18(6):678-82. PubMed ID: 12753150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
